about
sameAs
Survival in BRAF V600-mutant advanced melanoma treated with vemurafenibStructure-Guided Blockade of CSF1R Kinase in Tenosynovial Giant-Cell TumorReversing melanoma cross-resistance to BRAF and MEK inhibitors by co-targeting the AKT/mTOR pathway.Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in MelanomaModulation of cell signaling networks after CTLA4 blockade in patients with metastatic melanomaAnti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trialPD-1 blockade induces responses by inhibiting adaptive immune resistanceCorrelating animal and human phase Ia/Ib clinical data with CALAA-01, a targeted, polymer-based nanoparticle containing siRNA.Cixutumumab and temsirolimus for patients with bone and soft-tissue sarcoma: a multicentre, open-label, phase 2 trialNivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial.Adoptive transfer of MART-1 T-cell receptor transgenic lymphocytes and dendritic cell vaccination in patients with metastatic melanomaMulticenter phase II study of matured dendritic cells pulsed with melanoma cell line lysates in patients with advanced melanomaMultifunctional T-cell analyses to study response and progression in adoptive cell transfer immunotherapyPresentation of antagonist peptides to naive CD4+ T cells abrogates spatial reorganization of class II MHC peptide complexes on the surface of dendritic cells.Natural killer T cells in advanced melanoma patients treated with tremelimumabCTLA4 blockade induces frequent tumor infiltration by activated lymphocytes regardless of clinical responses in humans.A phase 2, multicenter, open-label study of sepantronium bromide (YM155) plus docetaxel in patients with stage III (unresectable) or stage IV melanomaPD-1 Blockade Expands Intratumoral Memory T Cells.Preexisting MEK1 exon 3 mutations in V600E/KBRAF melanomas do not confer resistance to BRAF inhibitorsGenomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma.Long term survival with cytotoxic T lymphocyte-associated antigen 4 blockade using tremelimumab.Ipilimumab: A First-in-Class T-Cell Potentiator for Metastatic Melanoma.CRAF R391W is a melanoma driver oncogeneRAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors.Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma.Safety and efficacy of stereotactic body radiation therapy in the treatment of pulmonary metastases from high grade sarcoma.Long-term outcome in BRAF(V600E) melanoma patients treated with vemurafenib: Patterns of disease progression and clinical management of limited progressionDendritic cell vaccination combined with CTLA4 blockade in patients with metastatic melanoma.Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapyKIT as a therapeutic target in metastatic melanoma.Single-institution, multidisciplinary experience with surgical resection of primary chest wall sarcomas.Clinical trial end points for assessing efficacy of novel therapies for soft-tissue sarcomas.Risk stratification of patients undergoing pulmonary metastasectomy for soft tissue and bone sarcomas.Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma.Antitumor effects of the investigational selective MEK inhibitor TAK733 against cutaneous and uveal melanoma cell lines.CD40 expression by human melanocytic lesions and melanoma cell lines and direct CD40 targeting with the therapeutic anti-CD40 antibody CP-870,893.Differential sensitivity of melanoma cell lines with BRAFV600E mutation to the specific Raf inhibitor PLX4032.The oncogenic BRAF kinase inhibitor PLX4032/RG7204 does not affect the viability or function of human lymphocytes across a wide range of concentrations.The specific T-cell response to antigenic peptides is influenced by bystander peptides.Imaging of CTLA4 blockade-induced cell replication with (18)F-FLT PET in patients with advanced melanoma treated with tremelimumab.
P50
Q24594790-E0F8EBB0-CC16-48C8-A2BD-259F357B0059Q27701677-7B14B9CC-CE38-4DC5-B535-B628EC40069EQ27851698-51520148-A975-4EF4-BBFC-F62EFF15139BQ27860650-35B52A19-4059-4F1D-A48A-E051A21A745CQ28749278-FC4D5EE7-2AEF-404A-BF83-3972AC31C398Q29620814-885CF739-E187-47DC-96AA-069B455A47BAQ29620856-68807B43-A145-494F-A091-7679D86044D5Q30837863-4A3DB439-F703-4EF3-B46F-A58D5BE9A3D3Q33406371-CF78AEAF-C2EA-4912-B7EE-6118A482DB8BQ33421351-EBE7C7FA-D18C-4A25-A418-C69F0BA2E359Q33806306-6043A70C-FB0C-4696-94AE-DCFAC3120FF0Q34198563-FD5FBF29-360F-4AC1-A1E6-31A65134E3C9Q34334598-D4172F8D-F611-418D-92FF-99A9E6EFACA6Q34380932-6E3CC709-8DE3-412A-9901-BCDF4CAD30BFQ35027661-17F29942-8A52-4673-AF02-DE7127B9D84DQ35053486-E50FDE15-8BFF-4EA2-822A-98B563D0FB34Q35602111-5183162C-0282-4D4F-9664-52C0D21FD08AQ36642804-5AD5C8B6-4B98-42B0-8E5A-E71334AA39F6Q36676466-7703CC78-443F-42FC-8D96-144F06860B37Q36730827-99EFCD97-3891-4DCD-BD73-E99C64A940B6Q36765800-D0D51942-72AF-4161-A23E-18235729A5A1Q36879912-BE829C30-6AEB-4F90-814C-DFF66DFAF64EQ36980239-9D83CBD2-BBBC-4311-B35C-3500D5EA663CQ37048053-97A562C7-EDCF-44C8-A885-E53358EB7E51Q37222679-91139593-6E7E-49A5-A664-80DA206B2CB9Q37254116-74AA54B1-9A81-43CC-A266-B714121E25E3Q37381163-B838F2B7-2A53-4B63-9375-B618A55F1781Q37394755-DFBA44F7-139A-4E3B-A648-C453F8779FCCQ37606223-0FCA776F-1264-4A87-8794-CDB207D4FDB4Q37701887-B3811591-5BC1-4886-A5F3-A0F9B2C5452BQ37981542-63F8CFA1-314D-40E5-91D2-B1B0C0E2DD79Q38055499-0712C29B-2CB3-414E-BF4C-8420E5F87D44Q38259860-57C56E02-489A-4C86-8194-B4732842B6CEQ38393470-16E24AAE-EEB2-4FAD-BE71-93CD67379CA0Q39362181-ADC7C3C3-A2BC-4154-863D-9882D0E8155CQ39655889-B78AE2A2-99F3-4B9C-8933-10A446CFA70CQ39712781-2C42072A-A2FF-4686-B183-6AAFF866120DQ39803993-02C213DD-1945-4F05-A4DA-8B5C34B2E2C7Q40254528-46E0900C-8964-4642-A3BC-66BAF2708D82Q43164814-9B803457-2DC5-4C50-9495-1DEFF1D132E3
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
ricercatore
@it
հետազոտող
@hy
name
Bartosz Chmielowski
@ast
Bartosz Chmielowski
@ca
Bartosz Chmielowski
@cs
Bartosz Chmielowski
@en
Bartosz Chmielowski
@es
Bartosz Chmielowski
@gl
Bartosz Chmielowski
@hr
Bartosz Chmielowski
@hsb
Bartosz Chmielowski
@it
Bartosz Chmielowski
@pl
type
label
Bartosz Chmielowski
@ast
Bartosz Chmielowski
@ca
Bartosz Chmielowski
@cs
Bartosz Chmielowski
@en
Bartosz Chmielowski
@es
Bartosz Chmielowski
@gl
Bartosz Chmielowski
@hr
Bartosz Chmielowski
@hsb
Bartosz Chmielowski
@it
Bartosz Chmielowski
@pl
prefLabel
Bartosz Chmielowski
@ast
Bartosz Chmielowski
@ca
Bartosz Chmielowski
@cs
Bartosz Chmielowski
@en
Bartosz Chmielowski
@es
Bartosz Chmielowski
@gl
Bartosz Chmielowski
@hr
Bartosz Chmielowski
@hsb
Bartosz Chmielowski
@it
Bartosz Chmielowski
@pl
P106
P1412
P1559
Bartosz Chmielowski
@pl
P21
P214
138145304389978570334
P27
P31
P3124
P496
0000-0002-2374-3320
P734
P735
P7859
lccn-n2016188731